Maintenance Immunosuppression

The contract between this chapter and the reader.

1. 1. Describe the standard maintenance regimen.
2. 2. Explain calcineurin inhibitors and their toxicities.
3. 3. Explain antimetabolites and their toxicities.
4. 4. Explain mTOR inhibitors and when they are used.
5. 5. Explain corticosteroids and steroid minimisation.
6. 6. Explain belatacept and its trade-offs.
7. 7. Individualise the regimen by risk and comorbidity.
8. 8. Anticipate the key drug interactions.
9. 9. Appraise the evidence behind regimen choices.

A sixty-second reading. Each bullet stands alone.

• The standard maintenance regimen is triple therapy: a calcineurin inhibitor, an antimetabolite, and a corticosteroid.
• Calcineurin inhibitors (tacrolimus, ciclosporin) are the cornerstone, blocking calcineurin to reduce interleukin-2 and T-cell activation.
• Calcineurin inhibitors are nephrotoxic and have a narrow therapeutic index requiring drug-level monitoring.
• Tacrolimus is generally preferred over ciclosporin and causes more post-transplant diabetes.
• Antimetabolites (mycophenolate, azathioprine) block lymphocyte proliferation; mycophenolate is preferred and is teratogenic.
• mTOR inhibitors (sirolimus, everolimus) spare the calcineurin inhibitor but impair wound healing and cause proteinuria.
• Corticosteroids are broadly immunosuppressive; minimisation or withdrawal reduces their toxicity at a modest cost in rejection.
• Belatacept blocks costimulation and spares the kidney from CNI nephrotoxicity, improving GFR, but causes more early rejection and is contraindicated in EBV-seronegative recipients.
• The regimen is individualised by immunologic risk and comorbidity.
• Calcineurin inhibitors interact via CYP3A4 — azoles and diltiazem raise levels; rifampicin lowers them.
• Azathioprine combined with allopurinol causes dangerous myelosuppression.
• Tacrolimus reduces rejection more than ciclosporin, and mycophenolate more than azathioprine.
• Drug levels and drug-specific toxicities are monitored throughout.

The medical core. An expert should agree maintenance immunosuppression is fully covered here.

Why it matters at the bedside

Maintenance immunosuppression is the prescription the patient lives on for the life of the graft. Get it right and the kidney is protected with tolerable side-effects; get it wrong in either direction and you trade the graft for rejection or the patient for diabetes, infection, and cancer. Knowing each drug — its target, its toxicities, its interactions — is the daily work of transplant medicine.

The standard regimen

• Modern maintenance is triple therapy: a calcineurin inhibitor, an antimetabolite, and a corticosteroid — three drugs hitting three different points in the alloimmune pathway, each at a dose lower than it would need alone. Most regimens build from this backbone, modifying it by immunologic risk and comorbidity.

Calcineurin inhibitors

• The calcineurin inhibitors — tacrolimus (preferred) and ciclosporin — are the cornerstone: they block calcineurin, cutting interleukin-2 production and T-cell activation (the signal-1/IL-2 axis). Their power comes with a narrow therapeutic index demanding level monitoring, and a signature toxicity — nephrotoxicity, both acute (afferent vasoconstriction) and chronic. They also cause post-transplant diabetes (more with tacrolimus), hypertension, hyperkalemia, tremor, and, rarely, thrombotic microangiopathy; ciclosporin adds gingival hyperplasia and hirsutism.

Antimetabolites

• Antimetabolites block lymphocyte proliferation by inhibiting purine synthesis. Mycophenolate is preferred — more effective than azathioprine — but causes gastrointestinal upset (diarrhoea) and myelosuppression and is teratogenic, so it must be stopped before pregnancy (azathioprine is the pregnancy-compatible alternative). Azathioprine's own trap is its interaction with allopurinol: blocking xanthine oxidase causes dangerous myelosuppression.

mTOR inhibitors

• The mTOR inhibitors, sirolimus and everolimus, also block proliferation (signal 3) and are used chiefly to spare the calcineurin inhibitor — to avoid its nephrotoxicity — or for their possible anti-malignancy effect. Their drawbacks are real: impaired wound healing (so they are avoided around surgery), proteinuria, mouth ulcers, hyperlipidaemia, pneumonitis, and worse delayed graft function if used too early.

Corticosteroids and steroid minimisation

• Corticosteroids are broadly immunosuppressive and long the backbone of the third agent — but they carry a heavy toxicity burden: diabetes, weight gain, bone loss, cataracts, and more. This has driven steroid-minimisation and early-withdrawal regimens, mainly in lower-risk patients, which reduce steroid toxicity at the cost of a modest increase in rejection — a genuine trade-off, not a free lunch.

Belatacept

• Belatacept is a costimulation blocker (a CTLA4-immunoglobulin fusion that interrupts signal 2), given by intravenous infusion. Its great appeal is that it spares the kidney from CNI nephrotoxicity and yields better long-term GFR and survival. Its costs are more early acute rejection and a strict contraindication in EBV-seronegative recipients, in whom it raises the risk of post-transplant lymphoproliferative disorder.

Individualising the regimen

• There is no single right regimen — it is tailored. Immunologic risk sets the intensity; comorbidity steers the choices: a diabetic or diabetes-prone patient may push toward steroid minimisation or a different CNI strategy, a history of malignancy toward an mTOR inhibitor, CNI nephrotoxicity toward belatacept (if EBV-seropositive), and pregnancy away from mycophenolate and mTOR inhibitors.

Drug interactions

• Two interaction families dominate. Calcineurin inhibitors are metabolised by CYP3A4, so azole antifungals, macrolides, diltiazem, and grapefruit raise their levels (toxicity), while rifampicin and some anticonvulsants lower them (rejection) — every co-prescription is checked. Separately, azathioprine plus allopurinol is a classic, dangerous combination causing profound myelosuppression.

Monitoring

• Maintenance is monitored continuously: calcineurin-inhibitor and mTOR-inhibitor levels by therapeutic drug monitoring (its own chapter), full blood counts for antimetabolite myelosuppression, lipids and urine protein for mTOR inhibitors, and glucose for steroid- and tacrolimus-induced diabetes. The regimen is a living thing, adjusted to levels, toxicities, and events.

The evidence base

• The choices rest on trials: tacrolimus reduces rejection more than ciclosporin, and mycophenolate more than azathioprine, which is why both are preferred; belatacept's pivotal trials showed better GFR and survival but more early rejection; and steroid-withdrawal trials quantify the toxicity-versus-rejection trade-off. The unresolved tension running through all of it is the efficacy of the calcineurin inhibitor against its nephrotoxicity.

Five fully-built tables.

Table A — The drug classes

Table B — Calcineurin inhibitors

Table C — Antimetabolites and mTOR inhibitors

Table D — Regimen variations

Table E — Key drug interactions

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — The cornerstone and its cost

CNI blocks calcineurin → less IL-2 → less T-cell activation, but afferent vasoconstriction and chronic injury → nephrotoxicity → ACTION: keep it as the cornerstone but monitor levels and consider sparing.

Chain 2 — Combination logic

Three drugs at three targets → lower individual doses → efficacy with less single-agent toxicity → ACTION: use triple therapy as the default.

Chain 3 — The CYP3A4 trap

CNI is metabolised by CYP3A4 → inhibitors (azoles, diltiazem) raise levels, inducers (rifampicin) lower them → toxicity or rejection → ACTION: check every co-prescription and adjust the CNI.

Chain 4 — Sparing the kidney

Belatacept blocks costimulation instead of calcineurin → no CNI nephrotoxicity → better GFR, but more early rejection and EBV/PTLD risk → ACTION: use belatacept in EBV-seropositive patients to spare the kidney.

Chain 5 — The antimetabolite hazards

Mycophenolate blocks purine synthesis → antiproliferative, but teratogenic and myelosuppressive → fetal harm and cytopenias → ACTION: stop before pregnancy (use azathioprine) and monitor the blood count.

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Maintenance regimen note

• Regimen: CNI (tacrolimus/ciclosporin) + antimetabolite (MMF/azathioprine) + steroid; or variation ___.
• Rationale / individualisation: risk; comorbidity (diabetes, malignancy, pregnancy); CNI-sparing ___.
• Targets and monitoring: CNI level ___; blood count ___; lipids/protein (mTOR) ___; glucose ___.
• EBV status (if belatacept): seropositive confirmed ___.
• Interaction checks (CYP3A4; azathioprine/allopurinol): ___.

Template 2 — Drug-interaction / regimen-change note

• New drug and interaction: e.g., azole (↑ CNI) / rifampicin (↓ CNI) / allopurinol (azathioprine).
• Effect on level/marrow and action taken: dose change / switch ___.
• Monitoring after the change: ___.
• Reason for any regimen switch (toxicity, pregnancy, malignancy, nephrotoxicity): ___.
• Follow-up plan: ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Metacognition anchored to this chapter's tensions. No answers provided.

1. 1. The calcineurin inhibitor is both the cornerstone of efficacy and a cause of chronic graft injury; how do you weigh protecting the graft now against harming it slowly?
2. 2. Steroid withdrawal trades visible long-term toxicity for a small, early rejection risk; whose values decide whether that trade is worth making?
3. 3. Belatacept offers a better long-term kidney at the price of more early rejection; how do you reason about a benefit that is deferred and a harm that is immediate?
4. 4. Every regimen is individualised, yet guidelines push toward a default; how do you decide when a patient's comorbidity justifies leaving the well-trodden path?
5. 5. Many of the worst events here are interactions and teratogenicity — entirely preventable; what systems would make you reliably catch them every time?

Nine items, each anchored in this chapter. At least one per objective.